The Patent Finder

Astellas Engineered Small Molecules US, Incorporated

14 patents currently held · Updated Nov 16, 2026
5 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

Previously recorded as Mitobridge, Inc. (to 2024)

0
Ending by 2030
Nov 2036
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 2 fees due Aug 27, 2027
  • 1 fee due Oct 7, 2027
    The maintenance fee for Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases (US 10,611,790) comes due Oct 7, 2027. Unpaid by Apr 7, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
PatentTitleStatus Expires Confidence
US 10,611,790Nicotinamide riboside and nicotinamide mononucleotide derivatives for use in the treatments of mitochondrial-related diseases
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,874,641Methods of Treating Acute Kidney Injury
In force
 · High confidence
In forceHigh confidence
US 10,927,094Crystalline and salt forms of PPAR agonist compounds
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,530,192Crystalline and salt forms of PPAR agonist compounds
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,912,681Crystalline and salt forms of PPAR agonist compounds
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,034,670Poly-Adp Ribose Polymerase (PARP) Inhibitors
In force
 · High confidence
In forceHigh confidence
US 11,168,080Dynamin-1-like protein inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 10,968,172USP30 inhibitors
In force
 · From the USPTO record
In forceFrom the USPTO record
US 11,993,585Poly-Adp Ribose Polymerase (PARP) Inhibitors
In force
 · Medium confidence
In forceMedium confidence
US 11,358,954PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof
In force
 · From the USPTO record
In forceFrom the USPTO record
10 of 14 patents shown.
Pro members see all 14.
Pro members: see all 14 patents
Also on record, not counted in the 14: 5 patents in force now held by others. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited